Communiqués GlycoMimetics, Inc.

Actions

GLYC

US38000Q1022

Temps Différé Nasdaq Autres places de cotation 21:14:48 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,315 ^USD	+1,61 %		+15,60 %	-86,63 %

04/06	Transcript : GlycoMimetics, Inc. - Special Call
04/06	GlycoMimetics annonce les résultats complets de l'étude pivot de phase 3 sur l'uproleselan dans la leucémie myéloïde aiguë (LMA) récurrente/réfractaire (R/R)	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed, Refractory Acute Myeloid Leukemia	05/06	AQ
GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	04/06	BU
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed, Refractory Acute Myeloid Leukemia on June 4, 2024	30/05	AQ
GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024	29/05	BU
GlycoMimetics: Q1 Earnings Snapshot	10/05	AQ
GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)	06/05	BU
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024	25/04	BU
GlycoMimetics: Q4 Earnings Snapshot	27/03	AQ
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023	27/03	BU
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024	13/03	BU
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference	26/02	BU
GlycoMimetics Reports Inducement Grant under NASDAQ Listing Rule 5635(4)	13/02	AQ
GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)	12/02	BU
GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687	04/01	BU
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia	03/01	AQ
GlycoMimetics Announces Independent Presentations on Uproleselan at American Society of Hematology Annual Meeting including New Clinical Data in Treated Secondary Acute Myeloid Leukemia	10/12	BU
GlycoMimetics to Participate in Upcoming Jefferies London Healthcare Conference	09/11	BU
GlycoMimetics: Q3 Earnings Snapshot	03/11	AQ
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023	03/11	BU
GlycoMimetics to Report Third Quarter 2023 Financial Results on November 3, 2023	23/10/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués GlycoMimetics, Inc.

Actions

GLYC

US38000Q1022

Communiqués

Filtres